Year: 2025
Type: article
Abstract: There is an increasing focus on personalized treatment approaches in advanced and metastatic urothelial carcinoma (mUC). Recent advancements include biomarker-driven therapy selection, novel antibody-drug conjugates (ADCs), immune checkpoint inhibitors, and targeted therapies. Managing treatment-related toxicities remains crucial, requiring interprofessional collaboration to monitor and mitigate adverse events. At JADPRO Live 2024, presenters discussed these considerations for advanced practitioners.
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4409003573